Expert Interview
Understanding the efficacy and safety profiles of Lunsekimig and Amlitelimab as potential treatments for atopic dermatitis and reactive airway disease.
Ticker(s): SNYInstitution: Private Practice
- Board-Certified dermatologist practicing cosmetic, medical, surgical and pediatric dermatology.
- Treats 5 patients with DEB and 100 patients with atopic dermatitis each month.
- Served as a sub-investigator for 10 randomized clinical drug trials for atopic dermatitis, psoriasis, systemic lupus erythematosus and cutaneous T-cell lymphoma; investigator for Dupixent’s Phase 2 AD trials.
What are your perceptions of Lunsekimig and Amlitelimab when treating Lunsekimig and Amlitelimab?
Added By: pharmaadvisorHow do you envision Lunsekimig fitting into the treatment algorithm alongside Dupixent and Amlitelimab?
Added By: pharmaadvisorWhat clinical data would you need to consider incorporating Lunsekimig into your treatment approach for asthma or atopic dermatitis?
Added By: pharmaadvisorWhat other disease conditions do you believe Lunsekimig is well suited for in future clinical trials?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
